​

IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IDYA Stock Forecast

IDEAYA Biosciences (IDYA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $52.38, with a high of $66.00 and a low of $27.00. This represents a 118.80% increase from the last price of $23.94.

$20 $30 $40 $50 $60 $70 High: $66 Avg: $52.38 Low: $27 Last Closed Price: $23.94

IDYA Stock Rating

IDEAYA Biosciences stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (85.71%), 2 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 2 12 Strong Sell Sell Hold Buy Strong Buy

IDYA Forecast vs Benchmarks

TypeNameUpside
StockIDEAYA Biosciences118.80%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-112
Avg Price Target-$27.00$55.08
Last Closing Price$23.94$23.94$23.94
Upside/Downside-12.78%130.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 252111--14
Dec, 243111--15
Nov, 247121--20
Oct, 24712---19
Sep, 24710---17
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Andrew BerensLeerink Partners$27.00$29.58-8.72%12.78%
Oct 24, 2024David DaiUBS$50.00$29.5069.49%108.86%
Sep 25, 2024Graig SuvannavejhMizuho Securities$55.00$31.3775.33%129.74%
Sep 23, 2024Corinne JenkinsGoldman Sachs$48.00$33.7342.31%100.50%
Sep 23, 2024Ben BurnettStifel Nicolaus$66.00$33.7395.67%175.69%
Sep 23, 2024Justin ZelinBTIG$62.00$33.8783.05%158.98%
Sep 10, 2024Ben BurnettStifel Nicolaus$68.00$36.9783.93%184.04%
Aug 27, 2024Yigal NochomovitzCitigroup$58.00$39.8045.73%142.27%
Aug 07, 2024Matthew BieglerOppenheimer$53.00$35.8647.80%121.39%
Jul 10, 2024Gregory RenzaRBC Capital$61.00$37.3363.41%154.80%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Leerink PartnersMarket Performdowngrade
Oct 24, 2024UBSBuyinitialise
Oct 15, 2024Cantor FitzgeraldOverweightinitialise
Sep 24, 2024RBC CapitalOutperformOutperformhold
Sep 23, 2024CitigroupBuyBuyhold
Sep 23, 2024Goldman SachsBuyBuyhold
Sep 23, 2024BTIGBuyBuyhold
Sep 23, 2024OppenheimerOutperformOutperformhold
Aug 27, 2024CitigroupBuyBuyhold
Aug 07, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.31$-1.35$-1.32$-1.96-----
Avg Forecast$-1.43$-1.23$-1.43$-1.91$-2.47$-2.72$-2.65$-2.72$-1.17
High Forecast$-3.01$-2.59$-3.88$-2.07$-2.56$-3.39$-3.98$-4.21$-3.18
Low Forecast$-0.61$-0.52$-0.24$-1.73$-2.36$-2.28$-0.84$0.03$-0.19
Surprise %-8.39%9.76%-7.69%2.62%-----

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.54M$27.94M$50.93M$23.39M-----
Avg Forecast$16.91M$33.97M$53.92M$28.28M$4.67M$16.04M$60.89M$91.67M$295.06M
High Forecast$9.44M$18.97M$19.30M$19.52M$1.67M$5.74M$58.55M$32.81M$105.61M
Low Forecast$31.36M$63.01M$124.81M$39.58M$10.80M$37.14M$63.24M$212.21M$683.05M
Surprise %15.55%-17.74%-5.53%-17.30%-----

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.27M$-47.53M$-54.81M$-112.96M-----
Avg Forecast$-82.06M$-70.62M$-82.47M$-112.96M$-141.31M$-163.02M$-138.49M$-205.28M$-67.49M
High Forecast$-173.25M$-149.09M$-223.44M$-119.24M$-147.10M$-194.84M$-228.86M$-242.18M$-182.86M
Low Forecast$-34.95M$-30.08M$-13.63M$-99.56M$-135.52M$-131.19M$-48.12M$1.99M$-11.15M
Surprise %-60.68%-32.69%-33.54%------

IDYA Forecast FAQ

Is IDEAYA Biosciences stock a buy?

IDEAYA Biosciences stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IDEAYA Biosciences is a favorable investment for most analysts.

What is IDEAYA Biosciences's price target?

IDEAYA Biosciences's price target, set by 14 Wall Street analysts, averages $52.38 over the next 12 months. The price target range spans from $27 at the low end to $66 at the high end, suggesting a potential 118.80% change from the previous close price of $23.94.

How does IDEAYA Biosciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

IDEAYA Biosciences stock forecast shows a 118.80% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for IDEAYA Biosciences over the past three months?

  • January 2025: 14.29% Strong Buy, 78.57% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 35.00% Strong Buy, 60.00% Buy, 5.00% Hold, 0% Sell, 0% Strong Sell.

What is IDEAYA Biosciences’s EPS forecast?

IDEAYA Biosciences's average annual EPS forecast for its fiscal year ending in December is -2.47 for 2024, a 26.02% increase from the reported $-1.96 in 2023. The prediction for 2025 is $-2.72, $-2.65 for 2026, $-2.72 for 2027, and $-1.17 for 2028.

What is IDEAYA Biosciences’s revenue forecast?

IDEAYA Biosciences's average annual revenue forecast for its fiscal year ending in December is $4.67M for 2024, a -80.04% decrease from the reported $23.38M in 2023. The forecast for 2025 is $16.04M, $60.89M for 2026, $91.67M for 2027, and $295.06M for 2028.

What is IDEAYA Biosciences’s net income forecast?

For its fiscal year ending in December, IDEAYA Biosciences's average annual net income forecast is $-141M for 2024, reflecting an 25.09% increase from the reported $-113M in 2023. The projection for 2025 is $-163M, $-138M for 2026, $-205M for 2027, and $-67.49M for 2028.